Intellia Therapeutics Terminates Hemophilia Pact with Regeneron
Friday, 22 March 2024, 16:40
Intellia Therapeutics Terminates Hemophilia Pact
Intellia Therapeutics has made the decision to terminate the co-development agreement with Regeneron Pharmaceuticals for the hemophilia gene editing therapy.
Continued Support for the Project
Despite the termination, Intellia will maintain its support for the project independently, indicating a strategic pivot in their partnership strategy.
Implications:
- Independent Development: Intellia will now take full control of advancing the gene editing therapy for hemophilia.
- Strategic Shift: The termination signifies a new direction in partnership collaborations for both companies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.